- Home
- HTBI vs SANA Comparison
HTBI vs SANA Comparison
Compare HTBI & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBI
- SANA
- Stock Information
- Founded
- HTBI 1926
- SANA 2018
- Country
- HTBI United States
- SANA United States
- Employees
- HTBI N/A
- SANA N/A
- Industry
- HTBI Savings Institutions
- SANA Medicinal Chemicals and Botanical Products
- Sector
- HTBI Finance
- SANA Health Care
- Exchange
- HTBI Nasdaq
- SANA Nasdaq
- Market Cap
- HTBI 641.9M
- SANA 522.4M
- IPO Year
- HTBI 2012
- SANA 2021
- Fundamental
- Price
- HTBI $36.22
- SANA $1.82
- Analyst Decision
- HTBI Buy
- SANA Strong Buy
- Analyst Count
- HTBI 4
- SANA 3
- Target Price
- HTBI $39.00
- SANA $11.50
- AVG Volume (30 Days)
- HTBI 40.4K
- SANA 1.8M
- Earning Date
- HTBI 01-22-2025
- SANA 11-08-2024
- Dividend Yield
- HTBI 1.30%
- SANA N/A
- EPS Growth
- HTBI 14.18
- SANA N/A
- EPS
- HTBI 3.52
- SANA N/A
- Revenue
- HTBI $187,440,000.00
- SANA N/A
- Revenue This Year
- HTBI N/A
- SANA N/A
- Revenue Next Year
- HTBI N/A
- SANA N/A
- P/E Ratio
- HTBI $10.52
- SANA N/A
- Revenue Growth
- HTBI 2.84
- SANA N/A
- 52 Week Low
- HTBI $23.55
- SANA $1.80
- 52 Week High
- HTBI $38.99
- SANA $12.00
- Technical
- Relative Strength Index (RSI)
- HTBI 49.03
- SANA 32.13
- Support Level
- HTBI $36.12
- SANA $1.80
- Resistance Level
- HTBI $37.24
- SANA $2.07
- Average True Range (ATR)
- HTBI 0.81
- SANA 0.28
- MACD
- HTBI -0.18
- SANA -0.02
- Stochastic Oscillator
- HTBI 20.90
- SANA 3.54
About HTBI HomeTrust Bancshares Inc.
HomeTrust Bancshares Inc operates as a bank holding company. It engaged in the business of planning, directing and coordinating the business activities of the Bank. The Bank is a North Carolina state chartered bank and provides a range of retail and commercial banking products.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.